Capital Fund Management S.A. Vir Biotechnology, Inc. Transaction History

Capital Fund Management S.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$23.2 - $27.29 $1.92 Million - $2.26 Million	-82,639 Reduced 73.85%	29,260 $717,000
Q1 2023 May 15, 2023	SELL	$22.26 - $30.85 $5.01 Million - $6.94 Million	-225,049 Reduced 66.79%	111,899 $2.6 Million
Q4 2022 Feb 13, 2023	BUY	$19.96 - $28.22 $445,447 - $629,785	22,317 Added 7.09%	336,948 $8.53 Million
Q3 2022 Nov 14, 2022	BUY	$18.26 - $31.1 $1.58 Million - $2.7 Million	86,797 Added 38.1%	314,631 $6.07 Billion
Q2 2022 Aug 12, 2022	BUY	$19.08 - $26.7 $399,134 - $558,537	20,919 Added 10.11%	227,834 $5.8 Million
Q1 2022 May 12, 2022	BUY	$21.19 - $40.01 $2.06 Million - $3.88 Million	97,076 Added 88.38%	206,915 $5.32 Million
Q4 2021 Feb 10, 2022	BUY	$30.97 - $54.03 $769,945 - $1.34 Million	24,861 Added 29.26%	109,839 $4.6 Million
Q3 2021 Nov 12, 2021	BUY	$34.9 - $54.54 $780,922 - $1.22 Million	22,376 Added 35.74%	84,978 $3.7 Million
Q2 2021 Aug 12, 2021	BUY	$38.75 - $51.0 $2.43 Million - $3.19 Million	62,602 New	62,602 $2.96 Million

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.